N/A N=20 Upper Limb Loss Perturbation Response
Amputation
Primary: Whole-body Angular Momentum in Sagittal-plane; Momentum of the Body in the Sagittal Plane of Walking Progression — 0.025; 0.031; 0.027; 0.028 Unitless (normalized)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=42 Subjective Wearing Experience of the Total30 for Astigmatism Lens Among Satisfied Biofinity Toric Lens Wearers
Astigmatism
Primary: Satisfaction With Comfort of T30fA Lens — 8 score on a scale
Phase 2 N=12 Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
Bariatric Surgery · Obesity · Weight Gain
Primary: Relative Change in Body Weight (%) — 0.033 Percent Change
Phase 3 N=410 Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Agitation Associated With Dementia of the Alzheimer's Type
Primary: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. — -11.7; -15.2; -8.0 units on a scale — p=< 0.0001
N/A N=20 Sex Differences in Vascular Responses to Exercise
Aging
Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation
N/A N=140 Incorporating Veterans' Preferences Into Lung Cancer Screening Decisions
Lung Cancer Screening
Primary: Decisional Conflict — 25.7; 29.9 units on a scale — p=0.18
Phase 1 N=19 A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.
Healthy Volunteers
Primary: AUCinf of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical…
N/A N=16,189 LLIN Evaluation in Uganda Project
Malaria
Primary: Malaria Incidence — 90466; 95898 episodes of malaria over 24 months
Phase 2 N=367 Gain-framed Messages and NRT for Lung Cancer Screening Patients
Lung Cancer Screening · Smoking Cessation
Primary: Smoking Cessation - Available Data — 15; 19 Participants
N/A N=11 Personalizing MPK Prescription
Transfemoral Amputation
Primary: Ten Meter Walking Test — 0.9963; 1.1051; 1.1111 Meters per second — p=0.126
Phase 1 N=24 A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955
Healthy
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 1; 1; 1 Participants
N/A N=108 Protecting Allies in Risky Situations
Sexual Assault · College Drinking · Behavioral Changes
Primary: Change in Readiness to Intervene on the Readiness Ruler — 7.22; 7.44; 8.60; 7.29 score on a scale
N/A N=300 Dashboard Activated Services and Tele-Health for Heart Failure
Heart Failure With Reduced Ejection Fraction
Primary: Optimization Potential Score — 2.9; 2.6 score on a scale
N/A N=65 Reward Function and Therapy for Late-Life Depression
Major Depressive Disorder
Primary: Change in Late Positive Potential to Rewarding Stimuli — 0.80; 0.07 microvolts — p=.08
Phase 2 N=51 A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
COVID-19 Prevention
Primary: Number of Adult Participants With Solicited Local Adverse Events (AEs) for 7 Days Post First Vaccination — 10; 5; 20 Participants